Clinical Trials Directory

Trials / Terminated

TerminatedNCT03213418

Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
11 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This project aims to develop electroretinogram as a new putative marker for dopamine release, and as a predictor of treatment response among patients seeking treatment for smoking cessation. Tobacco smoking continues to be a major public health challenge. Dopamine is a neurotransmitter released in the brain. Several lines of evidence suggest that dopamine release deficit in the brain is involved in the development and maintenance of nicotine dependence. The investigators hypothesize that smokers who do not have a deficit in dopamine release will more readily respond to behavioral treatment for smoking cessation, and in particular, financial incentives contingent on abstinence (Contingency Management). Previous pilot data suggest electroretinogram (ERG), which records electrical signals from the retina in response to light, is a clinically accessible correlate to dopamine release in the brain. The project proposes an ERG-based biomarker, and a pilot clinical trial to apply this biomarker to personalize smoking cessation treatment. This clinically tractable biomarker of central dopamine release may have a large number of future applications in the diagnosis and treatment of other mental illnesses and substance use disorders. The study will recruit normal controls and smokers, measure ERG before and after a standard dose of oral immediate release methylphenidate. Smokers will undergo a 12-week standardized treatment course of CM. The investigators will test whether smoking status and the response to CM are correlated to changes in ERG in response to methylphenidate challenge.

Conditions

Interventions

TypeNameDescription
BEHAVIORALContingency managementContingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.

Timeline

Start date
2018-02-01
Primary completion
2022-11-01
Completion
2022-12-01
First posted
2017-07-11
Last updated
2023-01-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03213418. Inclusion in this directory is not an endorsement.